Company Encyclopedia
View More
name
Xiao Fang Pharma
603207.SH
Shanghai Xiao Fang Pharmaceutical Co., Ltd produces and sells medicines in China. It offers medicines in the areas of gastroenterology, dermatology, orthopedics, otorhinolaryngology, and disinfection. Shanghai Xiao Fang Pharmaceutical Co., Ltd was founded in 1993 and is based in Shanghai, China.
3.093 T
603207.SHMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking56/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE19.02%A
    • Profit Margin42.31%A
    • Gross Margin63.39%A
  • Growth ScoreC
    • Revenue YoY6.89%C
    • Net Profit YoY8.50%C
    • Total Assets YoY-3.23%D
    • Net Assets YoY-11.45%D
  • Cash ScoreC
    • Cash Flow Margin236.35%C
    • OCF YoY6.89%C
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreA
    • Gearing Ratio19.39%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Xiao Fang Pharma: Net profit in the first three quarters increased by 5.09% year-on-year

    On October 24th, Xiao Fang Pharma released its Q3 2025 report, with third-quarter operating revenue of 127 million yuan, a year-on-year increase of 20.87%; net profit of 49.0727 million yuan, a year-on-year increase of 14.51%. For the first three quarters, operating revenue was 397 million yuan, a year-on-year increase of 8.17%; net profit was 170 million yuan, a year-on-year increase of 5.09%; basic earnings per share were 1.06 yuan

    Zhitong·
    SH
    603207
    -2.90%
    Zhitong·
    SH
    603207
    -2.90%

    Overview of A-share dividends and stock distributions: 18 stocks have their equity registration today

    Wind data shows that, according to the equity distribution plans of listed companies, 18 A-shares will have their equity registration today. Among them, 18 stocks plan to distribute dividends. In terms of dividend distribution, the equity registration date for the 18 stocks is October 17. CAYI, Sungrow Power Supply, and Xiao Fang Pharma have the highest dividend payouts, distributing 10.00 yuan, 9.50 yuan, and 7.00 yuan per 10 shares, respectively

    Zhitong·
    SZ
    301004
    -3.45%
    SZ
    300274
    -5.34%
    SH
    603207
    -2.90%
    Zhitong·
    SZ
    301004
    -3.45%
    SZ
    300274
    -5.34%
    SH
    603207
    -2.90%

    Xiao Fang Pharma entrusts BOJI CRO to develop traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture" (indication for hair loss)

    Xiao Fang Pharma and BOJI CRO signed a technical entrustment contract, in which BOJI CRO will assist in completing the clinical research and registration of the traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture." This cooperation marks an important progress for Xiao Fang Pharma in the field of innovative drugs, as both parties will leverage their respective advantages to enhance R&D efficiency and lay the foundation for product launch

    Zhitong·
    SH
    603207
    -2.90%
    SZ
    300404
    -5.08%
    Zhitong·
    SH
    603207
    -2.90%
    SZ
    300404
    -5.08%

    Overview of A-share lock-up stock release: Lock-up stocks worth 6.802 billion yuan are released today

    On Tuesday, 7 companies had their restricted shares unlocked, with a total unlock volume of 149 million shares and an unlock market value of 6.802 billion yuan. GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR, Jiacheng International, and Xiao Fang Pharma had the highest unlock volumes, at 86.0824 million shares, 33.2236 million shares, and 14.4 million shares, respectively. In terms of unlock market value, GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR, Xiao Fang Pharma, and Jiacheng International were 5.238 billion yuan, 512 million yuan, and 417 million yuan, respectively. The unlock ratio for GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR exceeded 10%, reaching 43.04%

    Zhitong·
    SH
    603207
    -2.90%
    SH
    688439
    -5.37%
    SH
    603535
    -3.77%
    Zhitong·
    SH
    603207
    -2.90%
    SH
    688439
    -5.37%
    SH
    603535
    -3.77%

    Xiao Fang Pharma released its semi-annual performance, with a net profit attributable to the parent company of 121 million yuan, a year-on-year increase of 1.69%

    According to the Zhitong Finance APP, Xiao Fang Pharma disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 270 million yuan, a year-on-year increase of 3.06%; net profit attributable to shareholders was 121 million yuan, a year-on-year increase of 1.69%; net profit excluding non-recurring items was 121 million yuan, a year-on-year increase of 2.04%; basic earnings per share were 0.75 yuan. The company plans to distribute a cash dividend of 7.00 yuan (including tax) for every 10 shares to all shareholders

    Zhitong·
    SH
    603207
    -2.90%
    Zhitong·
    SH
    603207
    -2.90%